BCD-264 is a monoclonal antibody being developed as a biosimilar to Darzalex (international nonproprietary name: daratumumab).
A monoclonal antibody is a protein created by scientists in the laboratory, similar to the immune system natural antibodies, designed to bind to a specific target in the human body1.
BCD-264 is one of the drug products in the clinical development program of BIOCAD.
- Weiner LM, Surana R., Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nature Reviews Immunology. 2010;10(5):317–27.
This section of the website includes information about an unauthorized investigational drug product for medical use.